State Street
TRDA icon

State Street’s Entrada Therapeutics TRDA Stock Holding History

State Street’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.39M Buy
596,677
+62,879
+12% +$603K ﹤0.01% 3075
2026
Q1 		$6.74M Buy
533,798
+25,009
+5% +$287K ﹤0.01% 2812
2025
Q4 		$5.23M Buy
508,789
+10,174
+2% +$85.8K ﹤0.01% 2973
2025
Q3 		$2.89M Buy
498,615
+2,753
+0.6% +$16.1K ﹤0.01% 3218
2025
Q2 		$3.33M Buy
495,862
+1,474
+0.3% +$11.9K ﹤0.01% 3110
2025
Q1 		$4.47M Sell
494,388
-10,591
-2% -$132K ﹤0.01% 2927
2024
Q4 		$8.73M Buy
504,979
+35,378
+8% +$641K ﹤0.01% 2707
2024
Q3 		$7.5M Buy
469,601
+24,385
+5% +$384K ﹤0.01% 2766
2024
Q2 		$6.34M Buy
445,216
+9,826
+2% +$140K ﹤0.01% 2815
2024
Q1 		$6.17M Buy
435,390
+7,558
+2% +$107K ﹤0.01% 2837
2023
Q4 		$6.46M Buy
427,832
+24,579
+6% +$364K ﹤0.01% 2823
2023
Q3 		$6.37M Buy
403,253
+12,062
+3% +$190K ﹤0.01% 2812
2023
Q2 		$5.92M Buy
391,191
+326,614
+506% +$4.5M ﹤0.01% 2914
2023
Q1 		$936K Buy
64,577
+54
+0.1% +$721 ﹤0.01% 3549
2022
Q4 		$872K Buy
64,523
+31,229
+94% +$547K ﹤0.01% 3589
2022
Q3 		$525K Buy
33,294
+3,100
+10% +$39.4K ﹤0.01% 3762
2022
Q2 		$368K Sell
30,194
-121,000
-80% -$918K ﹤0.01% 3959
2022
Q1 		$1.42M Buy
151,194
+70,075
+86% +$751K ﹤0.01% 3692
2021
Q4 		$1.39M Buy
+81,119
New +$1.97M ﹤0.01% 3741

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

State Street's TRDA Position: Q2 2026 in Review

State Street increased its Entrada Therapeutics (TRDA) stake by 12% in Q2 2026, buying an estimated $603K and bringing the position to 596,677 shares worth $4.39M. The position accounts for ﹤0.01% of the portfolio, ranked #3075.

State Street first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $8.73M in Q4 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • State Street held 596,677 shares of Entrada Therapeutics worth $4.39M as of Q2 2026.
  • State Street bought 62,879 Entrada Therapeutics shares in Q2 2026, an estimated $603K.
  • Entrada Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3075 holding.
  • State Street first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • State Street's Entrada Therapeutics position peaked at $8.73M in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.